Serimmune, Inc., a leader in understanding the functional antibody repertoire’s role in human disease, announced today that the company is enrolling 2,000 research participants in a study designed to understand the human immune response to SARS-CoV-2, the virus that causes COVID-19
April 13, 2021
· 2 min read